Breaking News Instant updates and real-time market news.

WVE

Wave Life Sciences

$24.51

-9.545 (-28.03%)

14:36
04/16/19
04/16
14:36
04/16/19
14:36

Wave Life Sciences downgraded to Hold from Buy at Stifel

  • 16

    Apr

  • 16

    Apr

WVE Wave Life Sciences
$24.51

-9.545 (-28.03%)

11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
12/06/18
12/06/18
NO CHANGE

Mizuho defending Wave Life Sciences after stock decline
Mizuho analyst Salim Syed maintained a Buy rating and $65 price target on Wave Life Sciences, and defended the stock after its double digit decline. Syed said some of the decline was related to the broader market decline, as the tape is generally red, but some is Wave Life specific, as a lack of details in the company's recent press release has disappointed some investors. The analyst said he spoke to management and believes the decline is unwarranted, as management alleviated concerns regarding the drug trial.
04/16/19
LEER
04/16/19
NO CHANGE
LEER
Outperform
Wave Life Sciences suvodirsen data with little read-through for efficacy, says SVB Leerink
SVB Leerink analyst Mani Foroohar says that Wave Life Sciences' first-in-human safety data from the Phase I trial of suvodirsen in exon 51 skipping-amenable Duchenne Muscular Dystrophy shows that it was generally sage and well-tolerated up to the 5mg/kg dose, and notes the company has selected the 3.0mg/kg and 4.5mg/kg doses to pivotal trials. While the stock is trading down and investors seem to see negative read-throughs for the potential efficacy of suvodirsen at 5mg/kg, given that drisapersen was dosed at 6mg/kg in clinical trials, the analyst believes that due to differences in chemistry between the compounds, comparison of doses between drugs is not appropriate proxy of potential efficacy. Foroohar maintains his 30% probability of success on the suvodirsen program and reiterates an Outperform rating on the shares.
04/16/19
MZHO
04/16/19
NO CHANGE
Target $65
MZHO
Buy
Safety data from Wave Life's Exon-51 SAD DMD trial seems reasonably clean, says Mizuho
Mizuho analyst Salim Syed notes that Wave Life Sciences disclosed safety data from its Phase 1 Exon-51 SAD DMD trial, and based on this Phase 1 trial and preclinical work, the company has selected two doses to move forward into its Phase 2/3 trial, 3mg/kg and 4.5mg/kg. The analyst believes the safety data seems "reasonably clean," and that the Street should be not be getting hung up on the reported adverse events. Syed reiterates a Buy rating and $65 price target on the shares.

TODAY'S FREE FLY STORIES

SJI

South Jersey Industries

$31.46

-0.16 (-0.51%)

16:26
04/18/19
04/18
16:26
04/18/19
16:26
Hot Stocks
Elizabethtown Gas files rate case with NJBPU »

Elizabethtown Gas, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

BCBP

BCB Bancorp

$13.09

0.08 (0.61%)

16:21
04/18/19
04/18
16:21
04/18/19
16:21
Earnings
BCB Bancorp reports Q1 EPS 32c, consensus 30c »

Total cash and cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
04/18/19
04/18
16:20
04/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for April 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKE

Oneok

$69.13

-0.59 (-0.85%)

16:17
04/18/19
04/18
16:17
04/18/19
16:17
Hot Stocks
Oneok increases quarterly dividend 9% to 86.5c per share »

Oneok increased its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 22

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
04/18/19
04/18
16:17
04/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
04/18/19
04/18
16:16
04/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEP

Holly Energy Partners

$28.23

0.51 (1.84%)

16:16
04/18/19
04/18
16:16
04/18/19
16:16
Hot Stocks
Holly Energy Partners raises dividend to 67c per unit from 66.75c »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

HES

Hess Corp.

$65.87

-0.05 (-0.08%)

16:15
04/18/19
04/18
16:15
04/18/19
16:15
Hot Stocks
Hess Corp. announces 13th discovery offshore Guyana »

Hess Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 22

    May

  • 29

    May

16:15
04/18/19
04/18
16:15
04/18/19
16:15
General news
Breaking General news story  »

Week of 4/17 Fed Balance…

16:15
04/18/19
04/18
16:15
04/18/19
16:15
General news
Breaking General news story  »

Week of 4/8 Money Supply…

DTRM

Determine

$0.00

(0.00%)

16:13
04/18/19
04/18
16:13
04/18/19
16:13
Hot Stocks
Determine announces winding up, liquidation, and dissolution »

Determine announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRTA

Prothena

$10.67

-0.08 (-0.74%)

16:12
04/18/19
04/18
16:12
04/18/19
16:12
Hot Stocks
Prothena will explore potential business development opportunities for NEOD001 »

Prothena reports results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

FFIN

First Financial

$60.25

-0.32 (-0.53%)

16:11
04/18/19
04/18
16:11
04/18/19
16:11
Earnings
First Financial reports Q1 EPS 56c, consensus 56c »

Reports Q1 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

INDB

Independent Bank

$84.23

-0.98 (-1.15%)

16:11
04/18/19
04/18
16:11
04/18/19
16:11
Earnings
Independent Bank reports Q1 EPS $1.30, consensus $1.29 »

Reports Q1 NII $82.5M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 13

    May

  • 16

    May

EXPO

Exponent

$56.31

0.15 (0.27%)

16:11
04/18/19
04/18
16:11
04/18/19
16:11
Earnings
Exponent reports Q1 EPS 42c, consensus 36c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

SRCE

1st Source

$46.04

-0.68 (-1.46%)

16:11
04/18/19
04/18
16:11
04/18/19
16:11
Earnings
1st Source reports Q1 EPS 86c, consensus 85c »

According to Christopher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

AMNB

American National Bankshares

$35.04

-0.25 (-0.71%)

16:10
04/18/19
04/18
16:10
04/18/19
16:10
Earnings
Breaking Earnings news story on American National Bankshares »

American National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$60.71

0.56 (0.93%)

16:10
04/18/19
04/18
16:10
04/18/19
16:10
Hot Stocks
Lumentum sees revenue from datacom transceivers down $20M-$25M in Q4 »

Lumentum announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 28

    May

TRNO

Terreno Realty

$43.11

0.44 (1.03%)

16:09
04/18/19
04/18
16:09
04/18/19
16:09
Hot Stocks
Terreno Realty executes 192K sqm lease in Florida »

Terreno Realty announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 07

    May

  • 08

    May

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

, AKRX

Akorn

$2.77

-0.16 (-5.46%)

16:09
04/18/19
04/18
16:09
04/18/19
16:09
Hot Stocks
Innovus announces FDA approval for Akorn's ANDA for FlutiCare »

Innovus Pharmaceuticals…

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

AKRX

Akorn

$2.77

-0.16 (-5.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 07

    May

ISRG

Intuitive Surgical

$530.12

5.37 (1.02%)

16:09
04/18/19
04/18
16:09
04/18/19
16:09
Earnings
Intuitive Surgical says worldwide da Vinci procedures grew 18% »

Intuitive Surgical said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 25

    Apr

  • 03

    May

ISRG

Intuitive Surgical

$529.84

5.09 (0.97%)

16:07
04/18/19
04/18
16:07
04/18/19
16:07
Earnings
Intuitive Surgical reports Q1 EPS $2.61, consensus $2.70 »

Reports Q1 revenue $974M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 25

    Apr

  • 03

    May

UIHC

United Insurance

$16.45

0.28 (1.73%)

16:06
04/18/19
04/18
16:06
04/18/19
16:06
Hot Stocks
United Insurance estimates Q1 catastrophe losses of roughly $18M pre-tax »

United Insurance Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ADAP

Adaptimmune

$4.08

-0.23 (-5.34%)

16:05
04/18/19
04/18
16:05
04/18/19
16:05
Hot Stocks
Adaptimmune announces presentation of allogeneic SPEAR T-cell program at ASGCT »

Adaptimmune announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$145.34

-0.56 (-0.38%)

16:05
04/18/19
04/18
16:05
04/18/19
16:05
Hot Stocks
D.E. Shaw reports 5.0% passive stake in Wayfair »

D.E. Shaw disclosed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.